fbpx
Search
Close this search box.
Contact Us

Epilepsy Disorder Models

Contact Us

Home › CRISPR Model Creation › Neurodegenerative Diseases Models › Alzheimer’s Disease Models

Epilepsy disorder-relevant models that are sequence validated

According to Epilepsy Foundation, epilepsy is the fourth most common neurological disorder and affects people of all ages. Through basic and clinical research, top genes that are mutated in Epilepsy disorder have been identified.

However, it is complex and challenging to select the right mutants to study due to many choices of strains and alleles. In addition, researchers sometimes have doubts that a strain obtained from another source has not lost the mutation or undergone genetic drift.

 
Contact Us

Our goal is to create a curated, reliable library of strains that are relevant to Epilepsy disorder.  We have carefully selected:

  • Strains and genes that are associated with Epilepsy disorder
  • Genetic tests to validate the strains including PCR and sequencing

These sequence validated strains enable researchers to:

  • Screen for drugs with activity against Epilepsy
  • Rapidly identify impactful drugs
  • Test drug compounds on a whole organism
Contact Us

STRAIN

HUMAN GENE

ZEBRAFISH GENE

TYPE OF TRANSGENIC

WORM PHENOTYPE

  • ZEP STXBP1 Knock-out
  • STXBP1
  • stxbp1a
  • PTC - frameshift mutation leads to an early stop codon
  • Failure to hatch and hyperpigmentation
  • ZEP STXBP1 Morpholino
  • STXBP1
  • stxbp1a
  • MO - translation blocking morpholino
  • Failure to hatch and hyperpigmentation

STRAIN

HUMAN GENE

WORM GENE HOMOLOGUE

TYPE OF TRANSGENIC

WORM PHENOTYPE

  • EPY STXBP1 Knock-out
  • PSEN1 - 70% of all early onset Alzheimer’s
  • unc-18
  • Lof - entire coding sequence is removed
  • Uncoordination and Pumping rescued
  • EPY STXBP1 humanized
  • STXBP1 - Syntaxin-Binding Protein 1
  • unc-18
  • Humanization - human coding sequence integrated into worm genome
  • Uncoordinated - Pharyngeal pumping frequency reduced
  • EPY STXBP1 humanized C180Y variant
  • STXBP1(C180Y)
  • unc-18
  • Point mutation - clinical variant introduced into humanized sequence
  • Morphology and movement defects
  • EPY STXBP1 humanized R406H variant
  • STXBP1(R406H)
  • unc-18
  • Point mutation - clinical variant introduced into humanized sequence
  • Morphology and movement defects
  • EPY STXBP1 humanized R292H variant
  • STXBP1(R292H)
  • unc-18
  • Point mutation - clinical variant introduced into humanized sequence
  • Morphology and movement defects
  • EPY CACNA1A Knock-out
  • CACNA1A - Calcium Channel Voltage-dependent, P/Q-type, alpha-1A subunit
  • unc-2
  • Lof - point mutation resulting in early termination
  • Uncoordinated- Pharyngeal pumping frequency reduced
  • EPY FOXG1 Knockout
  • FOXG1
  • fkh-2
  • Lof - point mutation resulting in early termination
  • synthetic lethal, with pes-1

Key Advantages of the Epilepsy Disorder Models:

  • Ready-to-screen format enables quicker identification of drug impacts
  • Genetic mutations are validated with sequencing
  • Recommended reference strains selected for their relevance to Epilepsy
  • Consistent number of animals received
Contact Us

More Disease Modeling Services

Ready to get started?
Ready to connect with us to learn more about working with our company or our technology?
Submit your inquiry below & we will get back to you soon.

Table of Contents

stay on the cutting edge...

The InVivo Biosystems Newsletter is delivered to your inbox bi-weekly,
giving you all of the latest company updates, industry news, and more.

Sign Up

Built on a robust portfolio of CRISPR genome editing patents, InVivo Biosystems has established a comprehensive preclinical discovery and development platform. By leveraging alternative models and proprietary methods, we accelerate go-to-market timelines for pharmaceutical companies and beyond.

Quick Links
Contact Us

Headquarters: 1505 Westec Drive, Eugene, OR 97402

1.844.663.8749.

Facebook Twitter Linkedin
Copyright © 2022 InVivo Biosystems. All rights reserved.
Facebook Twitter Linkedin